-
Novobiocin Sodium: DNA Replication Workflow
2026-09-21
Novobiocin Sodium offers a time-resolved way to connect bacterial DNA replication with protoplast enlargement, membrane synthesis, and vacuole formation. This workflow translates a reference study into practical assay design, controls, optimization steps, and troubleshooting guidance for DNA damage and antibiotic resistance research.
-
3-Methyladenine: From Autophagy to Ferroptosis
2026-09-21
3-Methyladenine is more than a conventional autophagy inhibitor: its time-dependent PI3K activity creates a useful perturbation framework for testing how autophagy, ferroptosis, tumor survival, and migration intersect. This article translates findings on the NT5DC2–ACSL3 axis in bladder cancer into a rigorous experimental strategy while defining the compound’s translational limits.
-
Regulatory NADH/NAD+ Biosensor for Bacteria
2026-09-20
Liu, Landick, and Raman developed a genetically encoded, ratiometric NADH/NAD+ biosensor by coupling the redox-responsive bacterial transcription factor Rex to an engineered promoter-reporter system. The sensor revealed substantial redox differences among respiratory-chain mutants and enabled enrichment of rare high-NADH cells, establishing a practical route for noninvasive, high-throughput analysis of bacterial redox metabolism.
-
CK2 and ERK8 Inhibitor: LLPS Assay Logic
2026-09-19
This guide positions the CK2 and ERK8 inhibitor as a small molecule inhibitor for separating kinase signaling from biomolecular condensation. It connects B7464 assay design with the SARS-CoV-2 nucleocapsid LLPS study while clearly defining evidence, controls, and research limitations.
-
Imipenem in Antibacterial Research Workflows
2026-09-19
Imipenem gives researchers a mechanistically defined way to connect PBP inhibition with susceptibility, resistance, phagocytosis, and sepsis-model outcomes. This workflow-focused guide shows how to prepare, benchmark, troubleshoot, and extend Imipenem assays without confusing antibacterial activity with immune-response effects.
-
AMD-070 hydrochloride: CXCR4 Assay Workflows
2026-09-18
Build reproducible CXCR4/CXCL12 migration and immune-cell assays with AMD-070 hydrochloride, using concentration-response design, time-resolved readouts, and matched viability controls. The workflow connects WHIM-relevant biology with exploratory applications in Waldenström macroglobulinemia and antiviral research while clearly separating established evidence from hypothesis-generating experiments.
-
Adefovir: From HBV Potency to OAT1 Assays
2026-09-18
Adefovir (GS-0393) connects HBV polymerase inhibition with renal OAT1 transporter phenotyping. This article presents an assay-centered framework for interpreting potency, exposure, nonlinear elimination, and experimental design without conflating antiviral activity with transporter readouts.
-
Mavorixafor hydrochloride in CXCR4 Assays
2026-09-17
This scenario-driven guide explains how Mavorixafor hydrochloride, SKU A3174, can support better-controlled CXCR4 pathway, viability, proliferation, and cytotoxicity experiments. It focuses on formulation, assay compatibility, controls, interpretation, and practical supplier selection without treating product specifications as assay validation.
-
Mycophenolic Acid: Mechanism to Immune Assays
2026-09-17
Mycophenolic acid is a dehydrogenase inhibitor that connects guanine nucleotide metabolism with immune-cell function. This thought-leadership guide translates whole-blood immunometabolism findings into assay design, validation, translational positioning, and practical product-use guidance.
-
1-Phenyl-2-Pentanol and Hepatic Fibrosis
2026-09-16
This study identifies 1-phenyl-2-pentanol from Moringa oleifera leaves as an in vitro inhibitor of hepatic stellate-cell activation. By combining fibrosis-marker analysis, proteomics, and molecular docking, the work connects the compound’s activity with TGF-β1 and Wnt/β-catenin signaling while defining important limitations for translation.
-
MPP7, EMT, and Polarity in Ovarian Cancer
2026-09-15
The reference study links elevated MPP7 with poor prognosis and shows that MPP7 interference suppresses epithelial ovarian cancer cell growth, migration, and invasion while altering planar polarity. Its integrated use of database analysis, tissue immunohistochemistry, functional assays, transcriptomics, and Western blotting supports a model in which MPP7 may promote EMT through Wnt/β-catenin signaling.
-
AMD-070 Hydrochloride: Receptor Biology in WHIM
2026-09-15
AMD-070 hydrochloride is an oral CXCR4 antagonist whose value extends beyond receptor inhibition to disease-relevant modeling of WHIM syndrome. This article connects CXCR4 receptor-state biology, phase 3 evidence, assay design, and carefully bounded anti-HIV research applications.
-
SGI-1027 and Everolimus in Renal Cancer
2026-09-14
A 2024 Advanced Science study identifies SGI-1027 as a methuosis-inducing agent and shows that it cooperates with everolimus to restrict renal cancer growth, migration, and invasion. The combination links lysosomal membrane permeability with apoptosis and GSDME-dependent pyroptosis, providing a preclinical strategy for addressing limitations of everolimus-based therapy.
-
RBMS1 Loss Enables PD-L1 Blockade in TNBC
2026-09-14
The reference study identifies the RNA-binding protein RBMS1 as a post-transcriptional regulator of PD-L1 stability in immune-cold triple-negative breast cancer. Its experiments connect RBMS1 depletion to B4GALT1 mRNA destabilization, impaired PD-L1 glycosylation, enhanced PD-L1 degradation, and stronger responses to T-cell-based treatment strategies.
-
Adefovir Dipivoxil in Chronic Hepatitis B
2026-09-13
Hadziyannis and Papatheodoridis established a clinically focused framework for understanding adefovir dipivoxil as a nucleotide analog therapy for chronic hepatitis B, integrating its activation, HBV DNA polymerase inhibition, efficacy, resistance profile, and safety. The review remains useful for designing hepatitis B virus research workflows because it connects molecular chain termination with outcomes across HBeAg-positive, HBeAg-negative, and lamivudine-resistant disease.